Physician profile
Sarah E Dick
NPI 1225089493
$22,614.44
in general payments reported to CMS, 2019-2025
27 companies · $4,289 in 2025
The $4,289 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $178 · 2021: $772 · 2022: $1,507 · 2023: $11K · 2024: $3,680 · 2025: $4,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,601 · Consulting Fee: $8,458 · Travel and Lodging: $814 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,601.35 |
| Consulting Fee | $8,457.50 |
| Travel and Lodging | $814.06 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,988.72 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $3,487.86 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $2,821.51 | 2023-2024 | Vtama |
| Ucb, INC. | $2,551.69 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,794.22 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $1,505.85 | 2021-2025 | Opzelura |
| Genzyme Corporation | $1,379.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $966.69 | 2019-2025 | |
| Janssen Biotech, INC. | $745.70 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $587.20 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $576.39 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $561.45 | 2020-2024 | Otezla, Enbrel |
| Leo Pharma INC. | $443.76 | 2022-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $271.58 | 2020-2025 | Cabtreo, Jublia, Arazlo |
| Lilly USA, LLC | $242.77 | 2019-2025 | Taltz, Zepbound, Ebglyss |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2024 | Spevigo |
| Celgene Corporation | $107.99 | 2019 | |
| Sun Pharmaceutical Industries INC. | $97.45 | 2023-2024 | Absorica Ld, Winlevi |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Pfizer INC. | $65.03 | 2022-2025 | |
| Almirall LLC | $53.92 | 2019-2022 | |
| Allergan, INC. | $39.26 | 2019 | |
| Mayne Pharma Commercial LLC | $36.93 | 2020 | |
| Prugen, INC. Pharmaceuticals | $36.16 | 2019-2020 | |
| Sandoz INC. | $22.92 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $20.82 | 2019 | |
| Organon LLC | $18.46 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.